The effects of old, new and emerging medicines on metabolic aberrations in PCOS

Therapeutic Advances in Endocrinology and Metabolism

Volumn 3, Issue 1, 2012, Pages 27-47

  Bargiota, Alexandra ^a   Diamanti Kandarakis, Evanthia ^b  

^a University of Thessaly School of Medicine   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ATORVASTATIN; CLOMIFENE CITRATE; CYANOCOBALAMIN; CYPROTERONE ACETATE; FLUTAMIDE; FOLIC ACID; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; SIMVASTATIN; SPIRONOLACTONE; TRIACYLGLYCEROL; VITAMIN D;

ACUPUNCTURE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HERBAL MEDICINE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; LOW FAT DIET; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TEA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84857816331     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018812437355     Document Type: Article

References (212)

1. Anonymous (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994). Lancet 344 (8934): 1383–1389.
2. Apridonidze T. Essah P.A. Iuorno M.J. Nestler J.E. (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 (4): 1929–1935.
3. Archer J.S. Chang R.J. (2004) Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (5): 737–754.
4. Attia G.R. Rainey W.E. Carr B.R. (2001) Metformin directly inhibits androgen production in human thecal cells. Fertil. Steril. 76 (3): 517–524.
5. Azziz R. Woods K.S. Reyna R. Key T.J. Knochenhauer E.S. Yildiz B.O. (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89 (6): 2745–2749.
6. Baillargeon J-P Iuorno M.J. Nestler J.E. (2003) Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 46 (2): 325–340.
7. Banaszewska B. Duleba A.J. Spaczynski R.Z. Pawelczyk L. (2006) Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am. J. Obstet. Gynecol. 194 (5): 1266–1272.
8. Banaszewska B. Pawelczyk L. Spaczynski R.Z. Dziura J. Duleba A.J. (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J. Clin. Endocrinol. Metab. 92 (2): 456–461.
9. Barber T.M. Casanueva F.F. Karpe F. Lage M. Franks S. McCarthy M.I. et al. (2008) Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur. J. Endocrinol. 158 (4): 511–516.
10. Barnard L. Ferriday D. Guenther N. Strauss B. Balen A.H. Dye L. (2007) Quality of life and psychological well being in polycystic ovary syndrome. Hum. Reprod. 22 (8): 2279–2286.
11. Bergman R N van Citters G.W. Mittelman S.D. Dea M.K. Hamilton-Wessler M. Kim S.P. et al. (2001) Central role of the adipocyte in the metabolic syndrome. J. Investig. Med. 49 (1): 119–126.
12. Berneis K. Rizzo M. Lazzarini V. Lazzaroni V. Fruzzetti F. Carmina E. (2007) Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92 (1): 186–189.
13. Björntorp P. (1992) Metabolic abnormalities in visceral obesity. Ann. Med. 24 (1): 3–5.
14. Bruno R.V. de Avila M.A.P. Neves F.B. Nardi A.E. Crespo C.M.S. Sobrinho A.T.C. (2007) Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil. Steril. 88 (2): 510–512.
15. Cagnacci A. Paoletti A.M. Renzi A. Orrù M. Pilloni M. Melis G.B. et al. (2003) Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J. Clin. Endocrinol. Metab. 88 (8): 3621–3625.
16. Carmina E. Lobo R.A. (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril. 82 (3): 661–665.
17. Chan C.C.W. MWL Koo Ng E.H.Y. O-S Tang WSB Yeung P-C H.o. (2006) Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome–a randomized placebo-controlled trial. J. Soc. Gynecol. Investig. 13 (1): 63–68.
18. Chantre P. Lairon D. (2002) Recent findings of green tea extract AR 25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 9 (1): 3–8.
19. Chasan-Taber L. Willett W.C. Stampfer M.J. Hunter D.J. Colditz G.A. Spiegelman D. et al. (1997) A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care 20 (3): 330–335.
20. Chen B.Y. Yu J. (1991) Relationship between blood radioimmunoreactive beta-endorphin and hand skin temperature during the electro-acupuncture induction of ovulation. Acupunct Electrother Res 16(1-2): 1–5.
21. Chen Z-H Li J. Liu J. Zhao Y. Zhang P. Zhang M-X et al. (2008) Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am. J. Chin. Med. 36 (5): 939–951.
22. Chiu K.C. Chu A. Go V.L.W. Saad M.F. (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 79 (5): 820–825.
23. Christakou C.D. Diamanti-Kandarakis E. (2008) Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health (Lond Engl) 4 (6): 583–594.
24. Cibula D. Fanta M. Vrbikova J. Stanicka S. Dvorakova K. Hill M. et al. (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod. 20 (1): 180–184.
25. Cleasby M.E. Dzamko N. Hegarty B.D. Cooney G.J. Kraegen E.W. Ye J-M (2004) Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes 53 (12): 3258–3266.
26. Costello M.F. Shrestha B. Eden J. Johnson N.P. Sjoblom P. (2007) Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum. Reprod. 22 (5): 1200–1209.
27. de Leo V. la Marca A. Petraglia F. (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr. Rev. 24 (5): 633–667.
28. de Pergola G. (2000) The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int. J. Obes. Relat. Metab. Disord. 24 Suppl 2: S59–S63
29. Deeks A.A. Gibson-Helm M.E. Teede H.J. (2010) Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil. Steril. 93 (7): 2421–2423.
30. Desvergne B. Wahli W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (5): 649–688.
31. de Ugarte C.M. Bartolucci A.A. Azziz R. (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83 (5): 1454–1460.
32. Diamanti-Kandarakis E. Alexandraki K. Piperi C. Protogerou A. Katsikis I. Paterakis T. et al. (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. 36 (10): 691–697.
33. Diamanti-Kandarakis E. Alexandraki K. Protogerou A. Piperi C. Papamichael C. Aessopos A. et al. (2005) Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol. 152 (5): 749–756.
34. Diamanti-Kandarakis E. Kandaraki E. Christakou C. Panidis D. (2009) The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 10 (4): 431–441.
35. Diamanti-Kandarakis E. Kouli C. Tsianateli T. Bergiele A. (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. 138 (3): 269–274.
36. Diamanti-Kandarakis E. Kouli C.R. Bergiele A.T. Filandra F.A. Tsianateli T.C. Spina G.G. et al. (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84 (11): 4006–4011.
37. Diamanti-Kandarakis E. Mitrakou A. Hennes M.M. Platanissiotis D. Kaklas N. Spina J. et al. (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metab. Clin. Exp. 44 (4): 525–531.
38. Diamanti-Kandarakis E. Mitrakou A. Raptis S. Tolis G. Duleba A.J. (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83 (8): 2699–2705.
39. Diamanti-Kandarakis E. Spina G. Kouli C. Migdalis I. (2001) Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 86 (10): 4666–4673.
40. Diamanti-Kandarakis E. (2008) Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 10: e3.
41. Diamanti-Kandarakis E. Alexandraki K. Piperi C. Aessopos A. Paterakis T. Katsikis I. et al. (2007) Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metab. Clin. Exp. 56 (1): 129–134.
42. Diamanti-Kandarakis E. Baillargeon J-P Iuorno M.J. Jakubowicz D.J. Nestler J.E. (2003) A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88 (5): 1927–1932.
43. Diamanti-Kandarakis E. Christakou C.D. Kandaraki E. Economou F.N. (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 162 (2): 193–212.
44. Diamanti-Kandarakis E. Katsikis I. Piperi C. Kandaraki E. Piouka A. Papavassiliou A.G. et al. (2008) Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf) 69 (4): 634–641.
45. Diamanti-Kandarakis E. Livadas S. Katsikis I. Piperi C. Mantziou A. Aimilia M. et al. (2011) Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J. Bone Miner. Metab. 29 (2): 201–206.
46. Diamanti-Kandarakis E. Palioniko G. Alexandraki K. Bergiele A. Koutsouba T. Bartzis M. (2004) The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur. J. Endocrinol. 150 (6): 793–798.
47. Diamanti-Kandarakis E. Papailiou J. Palimeri S. (2006) Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr Endocrinol Rev 3 Suppl 1: 198–204.
48. Diamanti-Kandarakis E. Papavassiliou A.G. Kandarakis S.A. Chrousos G.P. (2007) Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol. Metab. 18 (7): 280–285.
49. Diamanti-Kandarakis E. Paterakis T. Kandarakis H.A. (2006) Indices of low-grade inflammation in polycystic ovary syndrome. Ann. N.Y. Acad. Sci. 1092: 175–186.
50. Diamanti-Kandarakis E. Piperi C. Alexandraki K. Katsilambros N. Kouroupi E. Papailiou J. et al. (2006) Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metab. Clin. Exp. 55 (4): 494–500.
51. Diamanti-Kandarakis E. Piperi C. Korkolopoulou P. Kandaraki E. Levidou G. Papalois A. et al. (2007) Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J. Mol. Med. 85 (12): 1413–1420.
52. Diamanti-Kandarakis E. Piperi C. Patsouris E. Korkolopoulou P. Panidis D. Pawelczyk L. et al. (2007) Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell Biol. 127 (6): 581–589.
53. Downs J.R. Clearfield M. Weis S. Whitney E. Shapiro D.R. Beere P.A. et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (20): 1615–1622.
54. Duleba Antoni J. Banaszewska B. Spaczynski R.Z. Pawelczyk L. (2006) Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil. Steril. 85 (4): 996–1001.
55. Dulloo A.G. Duret C. Rohrer D. Girardier L. Mensi N. Fathi M. et al. (1999) Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am. J. Clin. Nutr. 70 (6): 1040–1045.
56. Dunaif A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18 (6): 774–800.
57. Dunaif A. Segal K.R. Futterweit W. Dobrjansky A. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (9): 1165–1174.
58. Dvorak Z. Vrzal R. (2011) Berberine reduces insulin resistance: the roles for glucocorticoid receptor and aryl hydrocarbon receptor. Fertil. Steril. 95 (2): e7; author reply e8–9.
59. Economou F. Xyrafis X. Christakou C. Diamanti-Kandarakis E. (2011) The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond. Curr. Pharm. Des. 17 (9): 908–921.
60. Ehrmann D A Schneider D.J. Sobel B.E. Cavaghan M.K. Imperial J. Rosenfield R.L. et al. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82 (7): 2108–2116.
61. Ehrmann D A Barnes R.B. Rosenfield R.L. Cavaghan M.K. Imperial J. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1): 141–146.
62. Ehrmann David A. Kasza K. Azziz R. Legro R.S. Ghazzi M.N. (2005) Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 (1): 66–71.
63. Eisenberg D.M. Kessler R.C. Foster C. Norlock F.E. Calkins D.R. Delbanco T.L. (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N. Engl. J. Med. 328 (4): 246–252.
64. Escobar-Morreale H F Lasunción M.A. Sancho J. (2000) Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil. Steril. 74 (4): 816–819.
65. Eyvazzadeh A.D. Pennington K.P. Pop-Busui R. Sowers M. Zubieta J-K Smith Y.R. (2009) The role of the endogenous opioid system in polycystic ovary syndrome. Fertil. Steril. 92 (1): 1–12.
66. Falsetti L. Pasinetti E. (1995) Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 74 (1): 56–60.
67. Falsetti L. Gambera A. Platto C. Legrenzi L. (2000) Management of hirsutism. Am J Clin Dermatol 1 (2): 89–99.
68. Fleming R. Hopkinson Z.E. Wallace A.M. Greer I.A. Sattar N. (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J. Clin. Endocrinol. Metab. 87 (2): 569–574.
69. Florakis D. Diamanti-Kandarakis E. Katsikis I. Nassis G.P. Karkanaki A. Georgopoulos N. et al. (2008) Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond) 32 (4): 692–699.
70. Freundlich M. Quiroz Y. Zhang Z. Zhang Y. Bravo Y. Weisinger J.R. et al. (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 74 (11): 1394–1402.
71. Gambineri A. Pelusi C. Vicennati V. Pagotto U. Pasquali R. (2002) Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26 (7): 883–896.
72. Gambineri Alessandra Patton L. Vaccina A. Cacciari M. Morselli-Labate A.M. Cavazza C. et al. (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J. Clin. Endocrinol. Metab. 91 (10): 3970–3980.
73. Gambineri Alessandra Pelusi C. Genghini S. Morselli-Labate A.M. Cacciari M. Pagotto U. et al. (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 60 (2): 241–249.
74. Gaspard U. Scheen A. Endrikat J. Buicu C. Lefebvre P. Gerlinger C. et al. (2003) A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 67 (6): 423–429.
75. Girard J. (2001) [Mechanisms of action of thiazolidinediones]. Diabetes Metab. 27(2 Pt 2): 271–278.
76. Glueck C.J. Goldenberg N. Sieve L. Wang P. (2008) An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metab. Clin. Exp. 57 (7): 954–960.
77. Glueck C.J. Goldenberg N. Streicher P. Wang P. (2003) Metformin and gestational diabetes. Curr. Diab. Rep. 3 (4): 303–312.
78. Glueck C.J. Moreira A. Goldenberg N. Sieve L. Wang P. (2003) Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum. Reprod. 18 (8): 1618–1625.
79. Glueck C.J. Streicher P. Wang P. (2002) Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 3 (8): 1177–1189.
80. Goldberg T. Cai W. Peppa M. Dardaine V. Baliga B.S. Uribarri J. et al. (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104 (8): 1287–1291.
81. Goldenberg N.M. Wang P. Glueck C.J. (2003) An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin. Chim. Acta 332(1-2): 11–19.
82. González F. Rote N.S. Minium J. Kirwan J.P. (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab. Clin. Exp. 58 (7): 954–962.
83. Guido M. Romualdi D. Giuliani M. Suriano R. Selvaggi L. Apa R. et al. (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab. 89 (6): 2817–2823.
84. Gurnell M. Savage D.B. Chatterjee V.K.K. O'Rahilly S. (2003) The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J. Clin. Endocrinol. Metab. 88 (6): 2412–2421.
85. Hahn S. Haselhorst U. Tan S. Quadbeck B. Schmidt M. Roesler S. et al. (2006) Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes 114 (10): 577–583.
86. Halperin I.J. Kumar S.S. Stroup D.F. Laredo S.E. (2011) The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum. Reprod. 26 (1): 191–201.
87. Harborne L. Fleming R. Lyall H. Sattar N. Norman J. (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 (9): 4116–4123.
88. Harborne L.R. Sattar N. Norman J.E. Fleming R. (2005) Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J. Clin. Endocrinol. Metab. 90 (8): 4593–4598.
89. He C. Sabol J. Mitsuhashi T. Vlassara H. (1999) Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48 (6): 1308–1315.
90. Hoeger K. Davidson K. Kochman L. Cherry T. Kopin L. Guzick D.S. (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93 (11): 4299–4306.
91. Hofmann S.M. Dong H-J Li Z. Cai W. Altomonte J. Thung S.N. et al. (2002) Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51 (7): 2082–2089.
92. Holick M.F. (2007) Vitamin D deficiency. N. Engl. J. Med. 357 (3): 266–281.
93. Holmäng A. Mimura K. Lönnroth P. (2002) Involuntary leg movements affect interstitial nutrient gradients and blood flow in rat skeletal muscle. J. Appl. Physiol. 92 (3): 982–988.
94. Ibáñez L. Potau N. Marcos M.V. de Zegher F. (2000) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab. 85 (9): 3251–3255.
95. Ibáñez L. Valls C. Potau N. Marcos M.V. de Zegher F. (2000) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 85 (10): 3526–3530.
96. Ibáñez Lourdes Valls C. Cabré S. de Zegher F. (2004) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J. Clin. Endocrinol. Metab. 89 (9): 4716–4720.
97. Isaia G. Giorgino R. Adami S. (2001) High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24 (8): 1496.
98. Izquierdo D. Foyouzi N. Kwintkiewicz J. Duleba A.J. (2004) Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil. Steril. 82 Suppl 3: 1193–1197.
99. Jansen G. Lundeberg T. Kjartansson J. Samuelson U.E. (1989) Acupuncture and sensory neuropeptides increase cutaneous blood flow in rats. Neurosci. Lett. 97 (3): 305–309.
100. Jedel E. Waern M. Gustafson D. Landén M. Eriksson E. Holm G. et al. (2010) Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum. Reprod. 25 (2): 450–456.
101. Jedel Elizabeth Labrie F. Odén A. Holm G. Nilsson L. Janson P.O. et al. (2011) Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am. J. Physiol. Endocrinol. Metab. 300 (1): E37–E45
102. Jensterle M. Sebestjen M. Janez A. Prezelj J. Kocjan T. Keber I. et al. (2008) Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur. J. Endocrinol. 159 (4): 399–406.
103. Jing Z. Liang-Zhi X. Tai-Xiang W. Ying T. Yu-Jian J. (2008) The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol. Endocrinol. 24 (10): 590–600.
104. Jones D.R. Schmidt R.J. Pickard R.T. Foxworthy P.S. Eacho P.I. (2002) Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J. Lipid Res. 43 (3): 383–391.
105. Jonsdottir I H (2000) Special feature for the Olympics: effects of exercise on the immune system: neuropeptides and their interaction with exercise and immune function. Immunol. Cell Biol. 78 (5): 562–570.
106. Kahn J.A. Gordon C.M. (1999) Polycystic ovary syndrome. Adolesc Med 10 (2): 321–336.
107. Kalkhoff R.K. (1975) Effects of oral contraceptive agents on carbohydrate metabolism. J. Steroid Biochem. 6 (6): 949–956.
108. Karakurt F. Sahin I. Güler S. Demirbas B. Culha C. Serter R. et al. (2008) Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. Adv Ther 25 (4): 321–328.
109. Kaya C. Cengiz S.D. Satiroğlu H. (2009) Obesity and insulin resistance associated with lower plasma vitamin B 12 in PCOS. Reprod. Biomed. Online 19 (5): 721–726.
110. Kidson W. (1998) Polycystic ovary syndrome: a new direction in treatment. Med. J. Aust. 169 (10): 537–540.
111. Kimura Y. Hyogo H. Yamagishi S-ichi Takeuchi M. Ishitobi T. Nabeshima Y. et al. (2010) Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J. Gastroenterol. 45 (7): 750–757.
112. Kodaman P.H. Duleba A.J. (2008 a) Statins in the treatment of polycystic ovary syndrome. Semin. Reprod. Med. 26 (1): 127–138.
113. Kodaman P.H. Duleba A.J. (2008 b) HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs 68 (13): 1771–1785.
114. Komar C.M. (2005) Peroxisome proliferator-activated receptors (PPARs) and ovarian function–implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod. Biol. Endocrinol. 3: 41.
115. Korytkowski M.T. Mokan M. Horwitz M.J. Berga S.L. (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80 (11): 3327–3334.
116. Kotsa K. Yavropoulou M.P. Anastasiou O. Yovos J.G. (2009) Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil. Steril. 92 (3): 1053–1058.
117. Lamon-Fava S. Ordovas J.M. Schaefer E.J. (1999) Estrogen increases apolipoprotein (apo) A-I secretion in hep G 2 cells by modulating transcription of the apo A-I gene promoter. Arterioscler. Thromb. Vasc. Biol. 19 (12): 2960–2965.
118. Legro R S Kunselman A.R. Dodson W.C. Dunaif A. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84 (1): 165–169.
119. Legro R S Kunselman A.R. Dunaif A. (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111 (8): 607–613.
120. Lemay A. Dodin S. Turcot L. Déchêne F. Forest J-C (2006) Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum. Reprod. 21 (1): 121–128.
121. Lin R-T Tzeng C-Y Lee Y-C Ho W-J Cheng J-T Lin J-G et al. (2009) Acute effect of electroacupuncture at the Zusanli acupoints on decreasing insulin resistance as shown by lowering plasma free fatty acid levels in steroid-background male rats. BMC Complement Altern Med 9: 26.
122. Linde K. Niemann K. Meissner K. (2010) Are sham acupuncture interventions more effective than (other) placebos? A re-analysis of data from the Cochrane review on placebo effects. Forsch Komplementmed 17 (5): 259–264.
123. Lopez L.M. Grimes D.A. Schulz K.F. (2007) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev (2): CD006133.
124. Lord J. Thomas R. Fox B. Acharya U. Wilkin T. (2006) The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome–a randomised, double-blind, placebo-controlled trial. BJOG 113 (7): 817–824.
125. Lord J.M. Flight I.H.K. Norman R.J. (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (7421): 951–953.
126. Luque-Ramírez M. Alvarez-Blasco F. Botella-Carretero J.I. Martínez-Bermejo E. Lasunción M.A. Escobar-Morreale H.F. (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92 (7): 2453–2461.
127. Mannerås L. Jonsdottir I.H. Holmäng A. Lönn M. Stener-Victorin E. (2008) Low-frequency electro-acupuncture and physical exercise improve metabolic disturbances and modulate gene expression in adipose tissue in rats with dihydrotestosterone-induced polycystic ovary syndrome. Endocrinology 149 (7): 3559–3568.
128. Mastorakos G. Koliopoulos C. Creatsas G. (2002) Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril. 77 (5): 919–927.
129. Mastorakos G. Koliopoulos C. Deligeoroglou E. Diamanti-Kandarakis E. Creatsas G. (2006) Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil. Steril. 85 (2): 420–427.
130. McNeill A.M. Rosamond W.D. Girman C.J. Golden S.H. Schmidt M.I. East H.E. et al. (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 (2): 385–390.
131. Mittelman Steven D. van Citters G.W. Kirkman E.L. Bergman R.N. (2002) Extreme insulin resistance of the central adipose depot in vivo. Diabetes 51 (3): 755–761.
132. Moghetti P. Castello R. Negri C. Tosi F. Perrone F. Caputo M. et al. (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85 (1): 139–146.
133. Morin-Papunen L. Rautio K. Ruokonen A. Hedberg P. Puukka M. Tapanainen J.S. (2003) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 (10): 4649–4654.
134. Morin-Papunen L. Vauhkonen I. Koivunen R. Ruokonen A. Martikainen H. Tapanainen J.S. (2003) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. 88 (1): 148–156.
135. Muniyappa R. Montagnani M. Koh K.K. Quon M.J. (2007) Cardiovascular actions of insulin. Endocr. Rev. 28 (5): 463–491.
136. Nader S. Diamanti-Kandarakis E. (2007) Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod. 22 (2): 317–322.
137. Nader S. Riad-Gabriel M.G. Saad M.F. (1997) The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab. 82 (9): 3074–3077.
138. Naka K.K. Kalantaridou S.N. Kravariti M. Bechlioulis A. Kazakos N. Calis K.A. et al. (2011) Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil. Steril. 95 (1): 203–209.
139. Nestler J E (1997) Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin. Reprod. Endocrinol. 15 (2): 111–122.
140. Nestler J E Jakubowicz D.J. de Vargas A.F. Brik C. Quintero N. Medina F. (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83 (6): 2001–2005.
141. Nestler John E. (2008) Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358 (1): 47–54.
142. Nissen S.E. Wolski K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (24): 2457–2471.
143. Ozdemir S. Görkemli H. Gezginç K. Ozdemir M. Kiyici A. (2008) Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 103 (1): 44–49.
144. Palmert M.R. Gordon C.M. Kartashov A.I. Legro R.S. Emans S.J. Dunaif A. (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87 (3): 1017–1023.
145. Palomba S. Falbo A. Giallauria F. Russo T. Tolino A. Zullo F. et al. (2010) Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 33 (2): 246–251.
146. Palomba S. Falbo A. Zullo F. Orio F. Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30 (1): 1–50.
147. Paradisi G. Steinberg H.O. Hempfling A. Cronin J. Hook G. Shepard M.K. et al. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (10): 1410–1415.
148. Paradisi Giancarlo Steinberg H.O. Shepard M.K. Hook G. Baron A.D. (2003) Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 (2): 576–580.
149. Pasquali R. Gambineri A. Anconetani B. Vicennati V. Colitta D. Caramelli E. et al. (1999) The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin. Endocrinol. (Oxf) 50 (4): 517–527.
150. Pasquali R. Gambineri A. Biscotti D. Vicennati V. Gagliardi L. Colitta D. et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85 (8): 2767–2774.
151. Pelusi Carla Pasquali R. (2003) Polycystic ovary syndrome in adolescents: pathophysiology and treatment implications. Treat Endocrinol 2 (4): 215–230.
152. Phillips N. Duffy T. (1973) One-hour glucose tolerance in relation to the use of contraceptive drugs. Am. J. Obstet. Gynecol. 116 (1): 91–100.
153. Phy J.L. Conover C.A. Abbott D.H. Zschunke M.A. Walker D.L. Session D.R. et al. (2004) Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients. J. Clin. Endocrinol. Metab. 89 (7): 3561–3566.
154. Picard F. Auwerx J. (2002) PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22: 167–197.
155. Pierpoint T. McKeigue P.M. Isaacs A.J. Wild S.H. Jacobs H.S. (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (7): 581–586.
156. Pittas A.G. Lau J. Hu F.B. Dawson-Hughes B. (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92 (6): 2017–2029.
157. Preiss D.J. Sattar N. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int. J. Clin. Pract. 61 (4): 697–701.
158. Prelević G.M. Würzburger M.I. Trpković D. Balint-Perić L. (1990) Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol. Endocrinol. 4 (3): 157–168.
159. Raja-Khan N. Shuja S.A. Kunselman A.R. Hogeman C.S. Demers L.M. Gnatuk C.L. et al. (2011) Brachial artery conductance during reactive hyperemia is increased in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 155 (1): 49–53.
160. Raja-Khan N. Stener-Victorin E. Wu X. Legro R.S. (2011) The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am. J. Physiol. Endocrinol. Metab. 301 (1): E1-E10.
161. Rashidi B. Haghollahi F. Shariat M. Zayerii F. (2009) The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 48 (2): 142–147.
162. Rautio K. Tapanainen J.S. Ruokonen A. Morin-Papunen L.C. (2005) Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur. J. Endocrinol. 152 (2): 269–275.
163. Reaven G.M. (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (12): 1595–1607.
164. Rimm E.B. Manson J.E. Stampfer M.J. Colditz G.A. Willett W.C. Rosner B. et al. (1992) Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35 (10): 967–972.
165. Rodriguez-Cuenca S. Monjo M. Proenza A.M. Roca P. (2005) Depot differences in steroid receptor expression in adipose tissue: possible role of the local steroid milieu. Am. J. Physiol. Endocrinol. Metab. 288 (1): E200–E207
166. Romualdi D. Guido M. Ciampelli M. Giuliani M. Leoni F. Perri C. et al. (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod. 18 (6): 1210–1218.
167. Romualdi Daniela de Marinis L. Campagna G. Proto C. Lanzone A. Guido M. (2008) Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clin. Endocrinol. (Oxf) 69 (4): 562–567.
168. Sacks F.M. Pfeffer M.A. Moye L.A. Rouleau J.L. Rutherford J.D. Cole T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335 (14): 1001–1009.
169. Sahin Y. Unluhizarci K. Yilmazsoy A. Yikilmaz A. Aygen E. Kelestimur F. (2007) The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 67 (6): 904–908.
170. Santana L.F. de Sá M.F.S. Ferriani R.A. de Moura M.D. Foss M.C. dos Reis R.M. (2004) Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol. Endocrinol. 19 (2): 88–96.
171. Sathyapalan T. Kilpatrick E.S. Coady A-M Atkin S.L. (2009) The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 94 (1): 103–108.
172. Sato A. Sato Y. (1992) Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Neurosci. Res. 14 (4): 242–274.
173. Schneider J.G. Tompkins C. Blumenthal R.S. Mora S. (2006) The metabolic syndrome in women. Cardiol Rev 14 (6): 286–291.
174. Schuring A.N. Schulte N. Sonntag B. Kiesel L. (2008) Androgens and insulin–two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 48 (1): 9–15.
175. Seaman H.E. de Vries C.S. Farmer R.D.T. (2003) The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum. Reprod. 18 (3): 522–526.
176. Selimoglu H. Duran C. Kiyici S. Ersoy C. Guclu M. Ozkaya G. et al. (2010) The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J. Endocrinol. Invest. 33 (4): 234–238.
177. Sharma S.T. Wickham E.P. 3rd Nestler J.E. (2007) Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 13 (4): 373–379.
178. Shaw L.J. Bairey Merz C.N. Azziz R. Stanczyk F.Z. Sopko G. Braunstein G.D. et al. (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 93 (4): 1276–1284.
179. Shepherd J. Cobbe S.M. Ford I. Isles C.G. Lorimer A.R. MacFarlane P.W. et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 (20): 1301–1307.
180. Sherman K.J. Cherkin D.C. Ichikawa L. Avins A.L. Delaney K. Barlow W.E. et al. (2010) Treatment expectations and preferences as predictors of outcome of acupuncture for chronic back pain. Spine 35 (15): 1471–1477.
181. Soares E.M.M. Azevedo G.D. Gadelha R.G.N. Lemos TMAM Maranhão T.M.O. (2008) Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil. Steril. 89 (3): 649–655.
182. Soares G.M. Vieira C.S. de Paula Martins W. Dos Reis R.M. de Sá M.F.S. Ferriani R.A. (2009) Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int. J. Clin. Pract. 63 (1): 160–169.
183. Solomon C.G. Hu F.B. Dunaif A. Rich-Edwards J.E. Stampfer M.J. Willett W.C. et al. (2002) Menstrual cycle irregularity and risk for future cardiovascular disease. J. Clin. Endocrinol. Metab. 87 (5): 2013–2017.
184. Sørensen H.N. Treuter E. Gustafsson J.A. (1998) Regulation of peroxisome proliferator-activated receptors. Vitam. Horm. 54: 121–166.
185. Staels B. Fruchart J-C (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (8): 2460–2470.
186. Stener-Victorin E. Waldenström U. Tägnfors U. Lundeberg T. Lindstedt G. Janson P.O. (2000) Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 79 (3): 180–188.
187. Sun F. Yu J. (2000) The effect of a special herbal tea on obesity and anovulation in androgen-sterilized rats. Proc. Soc. Exp. Biol. Med. 223 (3): 295–301.
188. Tang T. Glanville J. Hayden C.J. White D. Barth J.H. Balen A.H. (2006) Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 21 (1): 80–89.
189. Tarkun I. Cetinarslan B. Türemen E. Sahin T. Cantürk Z. Komsuoglu B. (2005) Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur. J. Endocrinol. 153 (1): 115–121.
190. Teede H. Deeks A. Moran L. (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8: 41.
191. Trolle B. Flyvbjerg A. Kesmodel U. Lauszus F.F. (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum. Reprod. 22 (11): 2967–2973.
192. Uribarri J. Peppa M. Cai W. Goldberg T. Lu M. He C. et al. (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 14 (3): 728–731.
193. Villaseca P. Hormaza P. Cárdenas I. Oestreicher E. Arteaga E. (2004) Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 9 (3): 155–165.
194. Viollet B. Foretz M. Guigas B. Horman S. Dentin R. Bertrand L. et al. (2006) Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. (Lond.) 574(Pt 1): 41–53.
195. Vlassara H. Palace M.R. (2002) Diabetes and advanced glycation endproducts. J. Intern. Med. 251 (2): 87–101.
196. Vlassara Helen Cai W. Crandall J. Goldberg T. Oberstein R. Dardaine V. et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. USA. 99 (24): 15596–15601.
197. Vrbíková J. Cibula D. (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum. Reprod. Update 11 (3): 277–291.
198. Vrbikova J. Dvorakova K. Hill M. Starka L. (2006) Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary. Endocr Regul 40 (4): 119–123.
199. Vrbíková J. Stanická S. Dvoráková K. Hill M. Vondra K. Bendlová B. et al. (2004) Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur. J. Endocrinol. 150 (2): 215–223.
200. Vrbíková J. Vondra K. Cibula D. Dvoráková K. Stanická S. Srámková D. et al. (2005) Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum. Reprod. 20 (12): 3328–3332.
201. Wassmann S. Laufs U. Müller K. Konkol C. Ahlbory K. Bäumer A.T. et al. (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22 (2): 300–305.
202. Wehr E. Pilz S. Schweighofer N. Giuliani A. Kopera D. Pieber T.R. et al. (2009) Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur. J. Endocrinol. 161 (4): 575–582.
203. White A. Cummings M. Barlas P. Cardini F. Filshie J. Foster N.E. et al. (2008) Defining an adequate dose of acupuncture using a neurophysiological approach–a narrative review of the literature. Acupunct Med 26 (2): 111–120.
204. Wiegratz I. Kuhl H. (2004) Long-cycle treatment with oral contraceptives. Drugs 64 (21): 2447–2462.
205. Wild S. Pierpoint T. Jacobs H. McKeigue P. (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3 (2): 101–105.
206. Yamauchi T. Kamon J. Waki H. Murakami K. Motojima K. Komeda K. et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276 (44): 41245–41254.
207. Yang X. Zhang Y. Wu X. Bae C.S. Hou L. Kuang H. et al. (2011) Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300 (4): R869–R875
208. Yildirim B. Sabir N. Kaleli B. (2003) Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 79 (6): 1358–1364.
209. Zang M. Zuccollo A. Hou X. Nagata D. Walsh K. Herscovitz H. et al. (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG 2 cells. J. Biol. Chem. 279 (46): 47898–47905.
210. Zhang J. Li T. Zhou L. Tang L. Xu L. Wu T. et al. (2010) Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. Cochrane Database Syst Rev (9): CD007535.
211. Zhao L. Li W. Han F. Hou L. Baillargeon J-P Kuang H. et al. (2011) Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil. Steril. 95 (1): 461–463.
212. Zulian E. Sartorato P. Benedini S. Baro G. Armanini D. Mantero F. et al. (2005) Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J. Endocrinol. Invest. 28 (1): 49–53.